NVNO - Latest News
enVVeno Medical Corporation (NVNO), operates in Healthcare / Medical - Devices, trades on NASDAQ.
Market capitalization stands near $5.5M. Beta to the broader market is 1.07.
The article list below shows the most recent NVNO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent NVNO Headlines
enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
accessnewswire.com - Oct 2, 2026
Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve curren
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
accessnewswire.com - Sep 11, 2026
Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
accessnewswire.com - Aug 27, 2026
Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
accessnewswire.com - Aug 4, 2026
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatme
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
accessnewswire.com - Jul 31, 2026
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients Duri
How News Affects NVNO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NVNO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked NVNO news questions
- What is the latest NVNO news headline?
- The most recent NVNO headline (Oct 2, 2026) is "enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the NVNO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What NVNO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual NVNO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.